Search results

• 4-FA
  info - Home  https://psychonautwiki.org/wiki/File:Behandeling-4-fa-intoxicatie.pdf https://psychonautwiki.org/wiki/File:4-FA%20risicobeoordeling%20(2016)
  21 KB (3,439 words) - 15:42, 30 July 2022
• Molecular structure
  In order to maintain consistency across the wiki, images of molecular structures should be produced in a standardized format rather than obtained from
  19 KB (857 words) - 09:55, 15 September 2022
• Amphetamine
  action involves promoting release of the neurotransmitters dopamine and norepinephrine. It was first synthesized in 1887, but its psychostimulant effects were
  41 KB (5,610 words) - 19:01, 7 April 2024
• Naturally occurring sources
  acuminata - DMT-Nexus Wiki  Acacia baileyana Wikipedia | https://en.wikipedia.org/wiki/Acacia_baileyana Acacia baileyana - DMT-Nexus Wiki  Acacia burkittii
  70 KB (630 words) - 04:11, 16 May 2024
• Methamphetamine
  releases a dopamine:norepinephrine ratio of ~1:1.3 from synapses versus ~1:2 for d-amphetamine. Their effect on the norepinephrine (NET) and dopamine (DAT)
  41 KB (5,798 words) - 13:29, 16 April 2024
• 4-FMA
  but it likely produces its effects by increasing levels of dopamine, norepinephrine, and serotonin in the brain. 4-FMA was first detected being sold in
  21 KB (3,467 words) - 16:14, 30 July 2022
• MDPV
  thought to act primarily as a potent norepinephrine-dopamine reuptake inhibitor. Reduced re-uptake of norepinephrine and dopamine results in higher concentrations
  23 KB (3,267 words) - 23:45, 21 April 2024
• MDMA
  produces its effects by promoting the release of serotonin, dopamine, and norepinephrine in the brain, particularly serotonin. MDMA was first developed in 1912
  85 KB (10,499 words) - 14:24, 16 April 2024
• 6-APB
  6-APB is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) with Ki values of 117, 150, and 2698 nM for the norepinephrine transporter (NET),
  33 KB (4,870 words) - 14:34, 16 April 2024
• Stimulants
  are increasing concentrations of the neurotransmitters dopamine and norepinephrine by either promoting release (e.g. amphetamine, methamphetamine) or by
  11 KB (1,055 words) - 02:52, 12 May 2024
• Antidepressants (section Norepinephrine and dopamine reuptake inhibitors (NDRIs))
  MAOIs (MAOIs) Norepinephrine and dopamine reuptake inhibitors (NDRIs) Selective serotonin reuptake inhibitors (SSRIs) Serotonin and norepinephrine reuptake
  9 KB (1,069 words) - 21:47, 13 May 2024
• Tramadol
  acts as a weak μ-opioid receptor agonist and a reuptake inhibitor of norepinephrine and serotonin. Tramadol was developed in 1962 and launched under the
  22 KB (3,211 words) - 19:11, 7 April 2024
• Methylphenidate
  as a norepinephrine-dopamine reuptake inhibitor (NDRI). It is most active at modulating levels of dopamine and, to a lesser extent, norepinephrine. Methylphenidate
  31 KB (4,254 words) - 15:15, 6 May 2024
• Opioids
  through the interaction of the mu receptors with serotonin, dopamine, and norepinephrine. Activation of mu receptors allows for the disinhibition of serotonin
  19 KB (2,797 words) - 02:47, 12 May 2024
• 3-MMC
  mechanism of action is not fully studied, but dopamine and serotonin and norepinephrine releasing activity is known to be involved. 3-MMC first appeared on
  18 KB (2,590 words) - 21:20, 30 April 2024
• 2-FMA
  acts as both a dopamine and norepinephrine releasing agent. This means it effectively increases the levels of the norepinephrine and dopamine in the brain
  17 KB (2,934 words) - 17:24, 18 January 2024
• Isopropylphenidate
  reuptake inhibitor and a norepinephrine reuptake inhibitor, meaning that it effectively boosts the levels of the norepinephrine and dopamine neurotransmitters
  19 KB (2,684 words) - 18:04, 30 July 2022
• 2-FA
  primarily as both a dopamine and norepinephrine releasing agent. This means it effectively increases the levels of the norepinephrine and dopamine neurotransmitters
  17 KB (3,024 words) - 17:25, 18 January 2024
• 3-FPM
  produces its activity by increasing the levels of serotonin, dopamine, and norepinephrine in the brain. The synthesis and pharmacology of 3-FPM was first reported
  15 KB (2,265 words) - 06:42, 8 September 2023
• Cocaine
  mechanism of action involves increasing levels of serotonin, dopamine, and norepinephrine in the brain.[citation needed] Cocaine is one of the most widespread
  47 KB (6,322 words) - 08:08, 3 May 2024
• MDAI
  serotonin releasing agent (SSRA) with neglible effects on dopamine and norepinephrine. MDAI was developed by the American medicinal chemist and pharmacologist
  17 KB (2,560 words) - 07:40, 12 October 2023
• A-PVP
  which includes compounds like MDPV, hexen, and a-PHP. It acts as a norepinephrine-dopamine reuptake inhibitor. α-PVP was patented in the 1960s by Boehringer
  24 KB (3,456 words) - 00:08, 3 November 2023
• Ethylphenidate
  dopamine reuptake inhibitor and norepinephrine reuptake inhibitor, meaning it effectively boosts the levels of the norepinephrine and dopamine neurotransmitters
  18 KB (2,561 words) - 14:02, 16 April 2024
• Mephedrone
  promoting the release of the neurotransmitters serotonin, dopamine, and norepinephrine in the brain.[citation needed] Mephedrone was first synthesized in 1929
  29 KB (3,963 words) - 14:23, 16 April 2024
• 2-Aminoindane
  acts as both a dopamine and norepinephrine releasing agent. This means it effectively boosts the levels of the norepinephrine and dopamine neurotransmitters
  12 KB (1,928 words) - 23:42, 21 April 2024
• Methylone
  Methylone acts as a mixed reuptake inhibitor/releasing agent of serotonin, norepinephrine, and dopamine. These neurotransmitters are thought to be responsible
  19 KB (2,841 words) - 14:21, 16 April 2024
• MDA
  (Ecstasy). As with MDMA, MDA is thought to act primarily as a serotonin-norepinephrine-dopamine reuptake inhibitor and releasing agent.[citation needed] However
  31 KB (4,379 words) - 12:23, 6 May 2024
• 1V-LSD
  likely similar to that of LSD, which acts on serotonin, dopamine, and norepinephrine receptors in the brain. 1V-LSD is a research chemical that appears to
  28 KB (3,658 words) - 15:27, 10 March 2023
• 4F-MPH
  primarily as a dopamine and norepinephrine reuptake inhibitor, meaning it effectively boosts the levels of dopamine and norepinephrine neurotransmitters in the
  16 KB (2,465 words) - 15:45, 9 May 2024
• Hexedrone
  most likely acts as both a dopamine and norepinephrine reuptake inhibitor. This allows dopamine and norepinephrine to build up within the brain, resulting
  8 KB (961 words) - 23:45, 21 April 2024
• Desoxypipradrol
  dementia. As with methylphenidate and pipradol, it is thought to act as a norepinephrine-dopamine reuptake inhibitor (NDRI). Of these three piperidines, it is
  19 KB (2,776 words) - 00:39, 1 August 2022
• Tapentadol
  of action, working on both the μ-opioid receptor and also acting as a norepinephrine reuptake inhibitor. Tapentadol is used in the management of moderate
  12 KB (2,182 words) - 23:51, 21 April 2024
• Prolintane
  thought to act primarily as a mild norepinephrine-dopamine reuptake inhibitor. Reduced re-uptake of norepinephrine and dopamine results in higher concentrations
  11 KB (1,751 words) - 20:42, 12 September 2022
• 3-FA
  dopamine and norepinephrine releasing agent, with modest selectivity for serotonin. This means it effectively increases the levels of the norepinephrine and dopamine
  15 KB (2,726 words) - 11:39, 17 February 2024
• Clonidine
  activity on the α2 receptors in the brainstem inhibits the release of norepinephrine (NE), resulting in decreased sympathetic nervous system tone. Clonidine
  22 KB (2,932 words) - 13:49, 16 April 2024
• Cyclazodone
  The mechanism of action involves promoting the release of dopamine and norepinephrine in the brain. Cyclazodone was developed in the 1960s by the American
  19 KB (2,675 words) - 16:54, 31 March 2024
• 3-FEA
  releaser of the monoamine neurotransmitters serotonin, dopamine, and norepinephrine. It has been demonstrated that compared to the unsubstituted ethylamphetamine
  19 KB (3,317 words) - 15:23, 30 July 2022
• Modafinil
  promote dopamine, norepinephrine, histamine, and hypocretin / orexin. Modafinil and its R-enantiomer, armodafinil, increase both norepinephrine (NE) and dopamine
  19 KB (3,104 words) - 11:29, 16 April 2024
• NEP
  serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) with very poor affinity for SERT. This allows dopamine, serotonin and norepinephrine to accumulate
  18 KB (2,677 words) - 06:56, 28 April 2024
• 5-MAPB
  in effect. 5-MAPB is a triple reuptake inhibitor for the monoamines norepinephrine, dopamine and serotonin as well as being an agonist for the 5-HT2A and
  13 KB (2,233 words) - 00:32, 31 December 2022
• A-PHP
  to the designer drug pentedrone and α-PVP, which both act as a potent norepinephrine-dopamine reuptake inhibitors (NDRI), although no substantial research
  21 KB (3,212 words) - 09:58, 30 May 2023
• MDEA
  and MDA. It produces its effects by increasing levels of serotonin, norepinephrine, and dopamine in the brain. The first recorded human use of MDEA was
  25 KB (3,654 words) - 23:46, 21 April 2024
• N-Ethylhexedrone
  about its pharmacology, although it likely acts by increasing levels of norepinephrine and dopamine in the brain. N-Ethylhexedrone was first synthesized by
  25 KB (3,455 words) - 23:45, 21 April 2024
• 2-FEA
  and that it releases the neurotransmitters: serotonin, dopamine, and norepinephrine. 2-FEA likely creates it effects by acting as a releasing agent of said
  13 KB (1,917 words) - 18:16, 30 April 2024
• Lisdexamfetamine
  its effects by promoting the release of neurotransmitters dopamine and norepinephrine in the brain. Subjective effects are essentially identical to that of
  23 KB (3,617 words) - 09:16, 17 April 2024
• Ephylone
  produces its effects by increasing levels of serotonin, dopamine, and norepinephrine in the brain. Ephylone was developed in the 1960s by Boehringer Ingelheim
  17 KB (2,604 words) - 22:15, 31 July 2022
• NM-2-AI
  acts as both a dopamine and norepinephrine releasing agent. This means it effectively boosts the levels of the norepinephrine and dopamine neurotransmitters
  11 KB (1,914 words) - 23:46, 21 April 2024
• 5-APB
  should be adjusted accordingly. 5-APB is a triple reuptake inhibitor for norepinephrine, dopamine and serotonin as well as being an agonist for the 5-HT2A 
  14 KB (2,336 words) - 23:43, 21 April 2024
• 3,4-CTMP
  acts as a dopamine and norepinephrine reuptake inhibitor, meaning it effectively boosts the levels of dopamine and norepinephrine neurotransmitters in the
  24 KB (3,701 words) - 23:42, 21 April 2024
• Ephedrine
  (family Ephedraceae). It works mainly by increasing the activity of norepinephrine (noradrenaline) on adrenergic receptors. It is most usually marketed
  13 KB (1,767 words) - 16:46, 7 April 2024

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)